{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"121.71","value":"259.44"},{"groupId":"OG001","spread":"120.45","value":"120.47"}]}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"115.10","value":"248.57"},{"groupId":"OG001","spread":"104.34","value":"184.54"}]}],"title":"Day 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"The apparent volume of distribution of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (λz).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with normal renal function (RF) received subcutaneous doses of azacitidine 75 mg/m\\^2 on Days 1 to 5.","id":"OG000","title":"Normal RF: Azacitidine 75 mg/m^2"},{"description":"Participants with severe renal impairment (RI) received subcutaneous doses of azacitidine 75 mg/m\\^2 on Days 1 to 5.","id":"OG001","title":"Severe RI: Azacitidine 75 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Population, consisting of all participants with evaluable plasma or urine concentration data for azacitidine. This analysis was performed for participants in the 2 treatment groups who received azacitidine treatment for 5 days.","reportingStatus":"POSTED","timeFrame":"Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose","title":"Apparent Volume of Distribution of Azacitidine (Vz/F) After Single and Multiple Doses of Azacitidine","type":"PRIMARY","unitOfMeasure":"liters"}